X
UnivadisfromMedscape
processing....
Originally classified as a glioma, medulloblastoma is referred to now as a primitive neuroectodermal tumor (PNET). This tumor accounts for approximately 7–8% of all intracranial tumors and 30% of pediatric brain tumors. Medulloblastoma is the most common malignant pediatric tumor in the central nervous system (CNS), accounting for nearly 20% of all childhood brain cancers and ~40% of all childhood tumors in the posterior fossa. This set of tumors is considered the most common brain malignancy among pediatric population. [2]
Symptoms are often progressive over weeks to months, and it is not uncommon for patients to have an extended symptomatic period prior to initial diagnosis. Metastatic disease is commonly present at diagnosis (40%), and imaging of the entire craniospinal axis is an essential part of the initial diagnostic evaluation. [8]
Symptoms usually differ by anatomic location of the tumor, presence of disseminated disease, and by the presence of hydrocephalus.
No specific biochemical test exists for the presence of medulloblastoma, although several molecular studies have revealed that histologically identical medulloblastomas are composed of distinct subgroups with different prognosis.
Imaging is the primary mode of monitoring residual disease, efficacy of continuing medical treatment, and recurrence or metastasis. Because medulloblastoma is aggressive, frequent monitoring is essential. MRI should be repeated every 3 months the first year; every 4-6 months the second year; and yearly thereafter.
Surgery is still the mainstay initial therapy for medulloblastoma, as both a tool for diagnosis and as a risk-stratification factor. The recommendation is still to go for the safest resection possible, and if a second surgery is needed it is better to do it before starting the adjuvant treatment.
Radiation therapy is an outpatient procedure typically performed at least 2 weeks following operative intervention in order to allow adequate surgical incision healing.
First used by Bailey and Cushing in 1925, [1]the term medulloblastoma described a series of tumors found in the cerebellum of children. Originally classified as a glioma, medulloblastoma is referred to now as a primitive neuroectodermal tumor (PNET). This tumor accounts for approximately 7–8% of all intracranial tumors and 30% of pediatric brain tumors. Medulloblastoma is the most common malignant pediatric tumor in the central nervous system (CNS), accounting for nearly 20% of all childhood brain cancers and ~40% of all childhood tumors in the posterior fossa. This set of tumors is considered the most common brain malignancy among pediatric population. [2]Medulloblastoma is a type of embryonal tumor. Embryonal tumors were described over the years as a collection of histologic entities that includes medulloblastoma and also included medulloepithelioma, CNS neuroblastoma, CNS ganglioneuroblastoma and atypical teratoid/rhabdoid tumor (ATRT) as well as primitive neuroectodermal tumors (PNET). All of that changed after the 2016 World Health Organization (WHO) reclassification. [3]
In the brain, medulloblastoma most often arises in the posterior fossa as shown in the image below. The tumor has the propensity of spreading throughout the CNS. Systemic metastases of this tumor, especially to bone, also have been recognized.
CT scan demonstrates a hyperdense lesion within the posterior fossa of an 8-year-old boy who presented with nausea and vomiting.Epidemiology data is changing ever since we have a better understanding of molecular and genetic behaviors of these tumors and especially after the new World Health Organization (WHO) classification from 2016. [3]
Age and Sex
Incidence of medulloblastoma is 1.5-2 cases per 100,000 population, with 350 new cases in the United States each year.
Medulloblastoma accounts for 64.3% of all embryonal tumors in pediatric patients (0–19 years old), according to the Central Brain Tumor Registry of the United States (CBTRUS). Males displayed higher incidence rate relative to females (males: 0.16 vs. females: 0.12), except in patients < 1 year-old. [2]Overall ratio tend to be 1.5:1 for males. Males also tend to have poorer prognosis. Among all age group, the reports from CBTRUS citing the embryonal tumor group together, with total incidence rate of 0.25 per 100,000 per year with slight male predominance (0.29 vs. 0.2). Incidence of medulloblastoma decreases with age. Incidence was 0.55 per 100,000 population, 0.57 per 100,000 population, 0.32 per 100,000 population, and 0.16 per 100,000 population in children aged 0–4, 5–9, and 10–14 years, and adolescents aged 15–19 years, respectively. Incidence was highest in patients aged 1–4 years at diagnosis, but patients aged 10–14 years showed increased incidence from 2000 to 2013, and when looking at all age groups the total incidence peaks at ages 9 years and below. When looking at CBTRUS and SEER databases covering roughly the same period of time (2000/2001 to 2013) adult patients (20 years of age and older) are about 28% from all medulloblastoma patients. Interestingly enough, for the adult group there was a significant rise in incidence rate between 2001 and 2009 with subsequent significant decline in the rate between 2009 and 2013. [2,4]
Race
In the United States, when looking at race for pediatric population (0-19 years), there is Caucasian and Asian/Pacific Islander predominance. In the collection of data from CBTRUS and SEER, white race was reported in the majority of cases (more than 80%). [2]Yet, when comparing black population to white population for the years 2001 to 2013, blacks displayed a non-significant increase in incidence and in mortality risk.
Mortality/Morbidity
The 5-year and 10-year survival rates among all patients are 73% and 64.7%, respectively. Patients aged 1–4 years have lower survival rates for each year post diagnosis relative to patients aged 5–9, 10–14, and 20+ years up to 5 years post diagnosis. Survival rates for males and females are similar up to 10 years post diagnosis. Black patients displayed slightly lower survival rates for each year post diagnosis compared to white patients. [2]Yet the reader needs to take into consideration that these survival numbers are from before the adjustment by molecular subtypes. When looking at the new classification (even before changing from 4 subtypes to 5), certain unsettled issues in epidemiology can become clearer. The group of infants < 1 year of age has a much poorer prognosis. In previous works it was described that the age group of children less than 4 years old are divided mainly to SHH (more than 50%) and group 3 (~40%). Whereas SHH pathway-driven tumors usually lead to a fair survival rate of 75% in 5 years for children below 3 years of age, group 3 for the same age group is having significantly worse survival rates. This accounts for the discrepancy between the old survival rates in CBTRUS of about 48% for children < 1 year old and 62% for children between 1 and 4 years of age, and the more positive picture that sometime can be seen in daily life. [5,6]
In terms of morbidity, there are a lot of potential causes and complications for the patient diagnosed with medulloblastoma:
Medulloblastoma is a very aggressive tumor. Even after a good response to surgery and radiation, recurrence is common; most recurrences occur within 2 years after treatment.
The most common location of recurrence is at the primary tumor site in the posterior fossa.
With the use of adjuvant chemotherapy, incidence of recurrence in the spinal canal and the supratentorial region seems to decrease.
Systemic metastases, in the absence of a CSF shunting system, are also a recognized problem in 10-20% of patients. Bone is the most common site of systemic metastasis; regional lymph node sites follow.
The Collin law was first hypothesized for Wilms tumor and has been expanded since to cover many pediatric tumors thought to be congenital in origin.
The Collin law states that if a tumor has not recurred in a period of time equal to age of the patient plus 9 months, that patient can be considered to be cured.
The Collin law generally holds for medulloblastoma, however, several late recurrences (longer than 10 years after diagnosis) have been reported. The 5-year progression-free survival rate in that group is 70–80% for patients at low risk and 60–70% for patients at high risk.
Greater age at diagnosis has been associated with a better prognosis, most likely because adults more often harbor the less aggressive desmoplastic variant of medulloblastoma.
Why females have a longer recurrence-free interval is not understood.
For discussion of prognosis by subtypes, see Approach Considerations.
Bailey P, Cushing H. A common type of midcerebellar glioma of childhood.Arch Neurol Psychiatr. 1925. 14:192-224.
Khanna V, Achey RL, Ostrom QT, Block-Beach H, Kruchko C et al. Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013.J Neurooncol. 2017 Aug 21.[QxMD MEDLINE Link].
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.Acta Neuropathol. 2016 Jun. 131 (6):803-20.[QxMD MEDLINE Link].
Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013.Neuro Oncol. 2016 Oct 1. 18 (suppl_5):v1-v75.[QxMD MEDLINE Link].
Kool M1, Korshunov A, Pfister SM. Update on molecular and genetic alterations in adult medulloblastoma. Sep 5,2012.[Full Text].
DeSouza RM, Jones BR, Lowis SP, Kurian KM. Pediatric medulloblastoma - update on molecular classification driving targeted therapies.Front Oncol. 2014. 4:176.[QxMD MEDLINE Link].
Robertson PL, Muraszko KM, Holmes EJ, Sposto R, Packer RJ, Gajjar A et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group.J Neurosurg. 2006 Dec. 105 (6 Suppl):444-51.[QxMD MEDLINE Link].
Srinivasan VM, Ghali MG, North RY, Boghani Z, Hansen D, Lam S. Modern management of medulloblastoma: Molecular classification, outcomes, and the role of surgery.Surg Neurol Int. 2016. 7 (Suppl 44):S1135-S1141.[QxMD MEDLINE Link].
Lanier JC, Abrams AN. Posterior fossa syndrome: Review of the behavioral and emotional aspects in pediatric cancer patients.Cancer. 2017 Feb 15. 123 (4):551-559.[QxMD MEDLINE Link].
Yap JL, Wachtel LE, Ahn ES, Sanz JH, Slomine BS, Pidcock FS. Treatment of cerebellar cognitive affective syndrome with aripiprazole.J Pediatr Rehabil Med. 2012. 5 (3):233-8.[QxMD MEDLINE Link].
Perreault S, Ramaswamy V, Achrol AS, Chao K, Liu TT, Shih D, et al. MRI surrogates for molecular subgroups of medulloblastoma.AJNR Am J Neuroradiol. 2014 Jul. 35 (7):1263-9.[QxMD MEDLINE Link].
Zitouni S, Koc G, Doganay S, Saracoglu S, Gumus KZ, Ciraci S et al. Apparent diffusion coefficient in differentiation of pediatric posterior fossa tumors.Jpn J Radiol. 2017 Aug. 35 (8):448-453.[QxMD MEDLINE Link].
Pierce TT, Provenzale JM. Evaluation of apparent diffusion coefficient thresholds for diagnosis of medulloblastoma using diffusion-weighted imaging.Neuroradiol J. 2014 Feb. 27 (1):63-74.[QxMD MEDLINE Link].
Keil VC, Warmuth-Metz M, Reh C, Enkirch SJ, Reinert C, Beier D et al. Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype.AJNR Am J Neuroradiol. 2017 Oct. 38 (10):1892-1898.[QxMD MEDLINE Link].
Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT et al. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.Cancer Cell. 2016 Apr 11. 29 (4):508-522.[QxMD MEDLINE Link].
Sengupta S, Pomeranz Krummel D, Pomeroy S. The evolution of medulloblastoma therapy to personalized medicine.F1000Res. 2017. 6:490.[QxMD MEDLINE Link].
Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L et al. Novel mutations target distinct subgroups of medulloblastoma.Nature. 2012 Aug 2. 488 (7409):43-8.[QxMD MEDLINE Link].
Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.Acta Neuropathol. 2013 Dec. 126 (6):917-29.[QxMD MEDLINE Link].
Chiang JC, Ellison DW. Molecular pathology of paediatric central nervous system tumours.J Pathol. 2017 Jan. 241 (2):159-172.[QxMD MEDLINE Link].
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.J Clin Oncol. 2013 Aug 10. 31 (23):2927-35.[QxMD MEDLINE Link].
Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.Cancer Cell. 2014 Mar 17. 25 (3):393-405.[QxMD MEDLINE Link].
Giordana MT, Schiffer P, Schiffer D. Prognostic factors in medulloblastoma.Childs Nerv Syst. 1998 Jun. 14(6):256-62.[QxMD MEDLINE Link].
Kahn M. Can we safely target the WNT pathway?.Nat Rev Drug Discov. 2014 Jul. 13 (7):513-32.[QxMD MEDLINE Link].
Shih DJ, Northcott PA, Remke M, Korshunov A, Ramaswamy V et al. Cytogenetic prognostication within medulloblastoma subgroups.J Clin Oncol. 2014 Mar 20. 32 (9):886-96.[QxMD MEDLINE Link].
Kiltie AE, Lashford LS, Gattamaneni HR. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old.Med Pediatr Oncol. 1997 May. 28(5):348-54.[QxMD MEDLINE Link].
Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.J Clin Oncol. 2011 Apr 10. 29 (11):1424-30.[QxMD MEDLINE Link].
Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes.Nature. 2012 Aug 2. 488 (7409):49-56.[QxMD MEDLINE Link].
Lin CY, Erkek S, Tong Y, Yin L, Federation AJ, Zapatka M, et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins.Nature. 2016 Feb 4. 530 (7588):57-62.[QxMD MEDLINE Link].
Schneider C, Ramaswamy V, Kulkarni AV, Rutka JT, Remke M, Tabori U et al. Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery.J Neurosurg Pediatr. 2015 Mar. 15 (3):236-42.[QxMD MEDLINE Link].
Rorke LB. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors.J Neuropathol Exp Neurol. 1983 Jan. 42(1):1-15.[QxMD MEDLINE Link].
Weitman DM, Cogen PH. Contemporary management of medulloblastoma.Contemporary Neurosurgery. 1998. 20(2):1-8.
Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas.Radiology. 1969 Dec. 93 (6):1351-9.[QxMD MEDLINE Link].
Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.Acta Neuropathol. 2016 Jun. 131 (6):821-31.[QxMD MEDLINE Link].
Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.J Clin Oncol. 1999 Mar. 17(3):832-45.[QxMD MEDLINE Link].
Rieken S, Mohr A, Habermehl D, Welzel T, Lindel K, Witt O, et al. Outcome and prognostic factors of radiation therapy for medulloblastoma.Int J Radiat Oncol Biol Phys. 2011 Nov 1. 81(3):e7-e13.[QxMD MEDLINE Link].
Rieken S, Gaiser T, Mohr A, Welzel T, Witt O, Kulozik AE, et al. Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept.BMC Cancer. 2010 Aug 23. 10:450.[QxMD MEDLINE Link].
Yock TI, Yeap BY, Ebb DH, Weyman E, Eaton BR, Sherry NA, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study.Lancet Oncol. 2016 Mar. 17 (3):287-98.[QxMD MEDLINE Link].
Gupta T, Jalali R, Goswami S, Nair V, Moiyadi A, Epari S, et al. Early Clinical Outcomes Demonstrate Preserved Cognitive Function in Children with Average-Risk Medulloblastoma When Treated with Hyperfractionated Radiation Therapy.Int J Radiat Oncol Biol Phys. 2012 Feb 16.[QxMD MEDLINE Link].
Haddy N, Mousannif A, Tukenova M, et al. Relationship between the brain radiation dose for the treatment of childhood cancer and the risk of long-term cerebrovascular mortality.Brain. 2011 May. 134:1362-72.[QxMD MEDLINE Link].
Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.J Clin Oncol. 2015 Aug 20. 33 (24):2646-54.[QxMD MEDLINE Link].
Martin AM, Raabe E, Eberhart C, Cohen KJ. Management of Pediatric and Adult Patients with Medulloblastoma.Curr Treat Options Oncol. 2014 Sep 7.[QxMD MEDLINE Link].
Adamski J, Ramaswamy V, Huang A, Bouffet E. Advances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumors.F1000Prime Rep. 2014. 6:56.[QxMD MEDLINE Link].[Full Text].
Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.Cancer Cell. 2014 Mar 17. 25 (3):393-405.[QxMD MEDLINE Link].
Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.Acta Neuropathol. 2012 Apr. 123 (4):473-84.[QxMD MEDLINE Link].
Salaroli R, Ronchi A, Buttarelli FR, Cortesi F, Marchese V, Bella ED, et al. Wnt activation affects proliferation, invasiveness and radiosensitivity in medulloblastoma.J Neurooncol. 2014 Sep 28.[QxMD MEDLINE Link].
Bode U, Zimmermann M, Moser O, Rutkowski S, Warmuth-Metz M, Pietsch T, et al. Treatment of recurrent primitive neuroectodermal tumors (PNET) in children and adolescents with high-dose chemotherapy (HDC) and stem cell support: results of the HITREZ 97 multicentre trial.J Neurooncol. 2014 Sep 2.[QxMD MEDLINE Link].
Yamada A, Moritake H, Kamimura S, Yamashita S, Takeshima H, Nunoi H. Proposed strategy for the use of high-dose chemotherapy with stem cell rescue and intrathecal topotecan without whole-brain irradiation for infantile classic medulloblastoma.Pediatr Blood Cancer. 2014 Aug 30.[QxMD MEDLINE Link].
Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group.Neurosurgery. 1996 Feb. 38(2):265-71.[QxMD MEDLINE Link].
Allen JC, Epstein F. Medulloblastoma and other primary malignant neuroectodermal tumors of the CNS. The effect of patients' age and extent of disease on prognosis.J Neurosurg. 1982 Oct. 57(4):446-51.[QxMD MEDLINE Link].
Ater JL, van Eys J, Woo SY, et al. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children.J Neurooncol. 1997 May. 32(3):243-52.[QxMD MEDLINE Link].
Bailey CC, Gnekow A, Wellek S, et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II.Med Pediatr Oncol. 1995 Sep. 25(3):166-78.[QxMD MEDLINE Link].
Balter-Seri J, Mor C, Shuper A, et al. Cure of recurrent medulloblastoma: the contribution of surgical resection at relapse.Cancer. 1997 Mar 15. 79(6):1241-7.[QxMD MEDLINE Link].
Blaser SI, Harwood-Nash DC. Neuroradiology of pediatric posterior fossa medulloblastoma.J Neurooncol. 1996 Jul. 29(1):23-34.[QxMD MEDLINE Link].
Carrie C, Muracciole X, Gomez F, et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol.Int J Radiat Oncol Biol Phys. 2005 Nov 1. 63(3):711-6.[QxMD MEDLINE Link].
Chang CH, Housepian EM, Herbert C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas.Radiology. 1969 Dec. 93(6):1351-9.[QxMD MEDLINE Link].
Cohen BH, Packer RJ. Chemotherapy for medulloblastomas and primitive neuroectodermal tumors.J Neurooncol. 1996 Jul. 29(1):55-68.[QxMD MEDLINE Link].
Dennis M, Spiegler BJ, Hetherington CR, et al. Neuropsychological sequelae of the treatment of children with medulloblastoma.J Neurooncol. 1996 Jul. 29(1):91-101.[QxMD MEDLINE Link].
Dufour C1, Kieffer V, Varlet P, Raquin MA, Dhermain F, Puget S, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuro-ectodermic tumors.[Full Text].
Dunkel IJ, Boyett JM, Yates A, Rosenblum M, Garvin JH Jr, Bostrom BC, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group.J Clin Oncol. 1998 Jan. 16(1):222-8.[QxMD MEDLINE Link].
Friedberg MH, David O, Adelman LS. Recurrence of medulloblastoma: violation of Collins' law after two decades.Surg Neurol. 1997 Jun. 47(6):571-4.[QxMD MEDLINE Link].
Giordana MT, Cavalla P, Dutto A, et al. Is medulloblastoma the same tumor in children and adults?.J Neurooncol. 1997 Nov. 35(2):169-76.[QxMD MEDLINE Link].
Giordana MT, Migheli A, Pavanelli E. Isochromosome 17q is a constant finding in medulloblastoma. An interphase cytogenetic study on tissue sections.Neuropathol Appl Neurobiol. 1998 Jun. 24(3):233-8.[QxMD MEDLINE Link].
Giralt J, Sánchez de Toledo J, Moraga F, et al. Improving survival of medulloblastoma: results in two groups of patients.Oncology. 1996 Jan-Feb. 53(1):38-42.[QxMD MEDLINE Link].
Hutzen B, Bid HK, Houghton PJ, Pierson CR, Powell K, Bratasz A, et al. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin. March,19,2014.[Full Text].
Hye Sook Min,* Ji Yeoun Lee,† Seung-Ki Kim,† and Sung-Hye Park*‡. Genetic Grouping of Medulloblastomas by Representative Markers in Pathologic Diagnosis1.[Full Text].
Jenkin D. The radiation treatment of medulloblastoma.J Neurooncol. 1996 Jul. 29(1):45-54.[QxMD MEDLINE Link].
Miralbell R, Bieri S, Huguenin P, et al. Prognostic value of cerebrospinal fluid cytology in pediatric medulloblastoma. Swiss Pediatric Oncology Group.Ann Oncol. 1999 Feb. 10(2):239-41.[QxMD MEDLINE Link].
Parsons DW1, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al. The genetic landscape of the childhood cancer medulloblastoma.[Full Text].
Pollack IF, Polinko P, Albright AL, et al. Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology.Neurosurgery. 1995 Nov. 37(5):885-93.[QxMD MEDLINE Link].
Rajurkar M1, Huang H, Cotton JL, Brooks JK, Sicklick J, McMahon AP, et al. Distinct cellular origin and genetic requirement of Hedgehog-Gli in postnatal rhabdomyosarcoma genesis.[Full Text].
Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A. Medulloblastoma: from molecular pathology to therapy.Clin Cancer Res. 2008 Feb 15. 14(4):971-6.[QxMD MEDLINE Link].
Rutka JT, Hoffman HJ. Medulloblastoma: a historical perspective and overview.J Neurooncol. 1996 Jul. 29(1):1-7.[QxMD MEDLINE Link].
Saran FH, Driever PH, Thilmann C, et al. Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation.Int J Radiat Oncol Biol Phys. 1998 Dec 1. 42(5):959-67.[QxMD MEDLINE Link].
Schmandt S, Kuhl J. Chemotherapy as prophylaxis and treatment of meningosis in children less than 3 years of age with medulloblastoma.J Neurooncol. 1998 Jun-Jul. 38(2-3):187-92.[QxMD MEDLINE Link].
Sure U, Berghorn WJ, Bertalanffy H. Collins' law. Prediction of recurrence or cure in childhood medulloblastoma?.Clin Neurol Neurosurg. 1997 May. 99(2):113-6.[QxMD MEDLINE Link].
Sutton LN, Phillips PC, Molloy PT. Surgical management of medulloblastoma.J Neurooncol. 1996 Jul. 29(1):9-21.[QxMD MEDLINE Link].
Tomita T. Medulloblastomas. Youmans JR, ed.Neurolgical Surgery. 5th ed. Philadelphia: WB Saunders; 1996. Vol 4: 2570-92.
Weil MD, Lamborn K, Edwards MS, Wara WM. Influence of a child's sex on medulloblastoma outcome.JAMA. 1998 May 13. 279(18):1474-6.[QxMD MEDLINE Link].
Whelan HT, Krouwer HG, Schmidt MH, et al. Current therapy and new perspectives in the treatment of medulloblastoma.Pediatr Neurol. 1998 Feb. 18(2):103-15.[QxMD MEDLINE Link].
Whittier KL1, Boese EA, Gibson-Corley KN, Kirby PA, Darbro BW, Qian Q, et al. G-protein coupled receptor expression patterns delineate medulloblastoma subgroups. Oct,10,2013.[Full Text].
Yang SY, Wang KC, Cho BK, et al. Radiation-induced cerebellar glioblastoma at the site of a treated medulloblastoma: case report.J Neurosurg. 2005 May. 102(4 Suppl):417-22.[QxMD MEDLINE Link].
Gajjar AJ, Robinson GW. Medulloblastoma-translating discoveries from the bench to the bedside.Nat Rev Clin Oncol. 2014 Dec. 11 (12):714-22.[QxMD MEDLINE Link].
Gururangan S, Robinson G, Ellison DW, Wu G, He X, Lu QR et al. Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations.Pediatr Blood Cancer. 2015 Oct. 62 (10):1855-8.[QxMD MEDLINE Link].
Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT et al. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.Cancer Cell. 2016 Apr 11. 29 (4):508-522.[QxMD MEDLINE Link].
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.J Clin Oncol. 2013 Aug 10. 31 (23):2927-35.[QxMD MEDLINE Link].
Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.Lancet Oncol. 2013 Nov. 14 (12):1200-7.[QxMD MEDLINE Link].
Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ et al. Medulloblastomics: the end of the beginning.Nat Rev Cancer. 2012 Dec. 12 (12):818-34.[QxMD MEDLINE Link].
Subtype | Age group | Molecular characteristics | Genetic mutations | Incidence | Prognosis (10-year overall survival) |
WNT activation | Found in children and adults (not infants) | WNT pathway activation | CTNNB1 DDX3X Chromatin-remodeling genes TP53 | Least common | Favorable 72% |
SHH activation | 5–18 years old | SHH pathway activation | TP53 | About 25% of the cases | Worse |
All age groups | SHH pathway activation | Non TP53 (wild type): PTCH1 SMO (mainly adults) SUFU (mainly infants) TERT promoter Chromatin-remodeling genes | If no MYCN amplification and no metastatic disease – favorable | ||
Group 3 | Infants and children (more common in boys than in girls) | Elevated expression of MYC GABRA5 over-expression | SMARCA4 Chromatin-remodeling genes Genes of TGF-β pathway | About 25% of the cases | If MYC amplification present – very poor prognosis Metastatic disease – very poor prognosis |
Group 4 | More common in children (not infants) than in adults | Lmx1A expression | Chromatin-remodeling genes | Most common | If no metastatic disease and chromosome 11 loss – favorable |
George I Jallo, MD Professor of Neurosurgery, Pediatrics, and Oncology, Director, Clinical Pediatric Neurosurgery, Department of Neurosurgery, Johns Hopkins University School of Medicine
George I Jallo, MD is a member of the following medical societies:American Association of Neurological Surgeons,American Medical Association,American Society of Pediatric Neurosurgeons
Disclosure: Nothing to disclose.
Brooks R Osburn, MD Resident Physician, Department of Neurosurgery, University of South Florida Morsani College of Medicine
Brooks R Osburn, MD is a member of the following medical societies:American Association of Neurological Surgeons,Congress of Neurological Surgeons
Disclosure: Nothing to disclose.
Nir Shimony, MD Assistant Professor of Neurological Surgery, Division of Pediatric Neurosurgery, Department of Surgery, St Jude Children’s Research Hospital, Le Bonheur Neuroscience Institute, Le Bonheur Children’s Hospital, Baptist Children’s Hospital, and Semmes Murphey Clinic, University of Tennessee Health Science Center College of Medicine; Adjunct Faculty, Department of Neurosurgery, Johns Hopkins University School of Medicine
Nir Shimony, MD is a member of the following medical societies:American Association of Neurological Surgeons,American Epilepsy Society,Congress of Neurological Surgeons,International Society of Pediatric Neurosurgery,Society for Neuro-Oncology
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Stephen L Nelson, Jr, MD, PhD, FAACPDM, FAAN, FAAP, FANA Professor of Pediatrics, Neurology, Neurosurgery, and Psychiatry, Medical Director, Tulane Center for Autism and Related Disorders, Tulane University School of Medicine; Pediatric Neurologist and Epileptologist, Ochsner Hospital for Children; Professor of Neurology, Louisiana State University School of Medicine
Stephen L Nelson, Jr, MD, PhD, FAACPDM, FAAN, FAAP, FANA is a member of the following medical societies:American Academy for Cerebral Palsy and Developmental Medicine,American Academy of Neurology,American Academy of Pediatrics,American Epilepsy Society,American Medical Association,American Neurological Association,The Society of Federal Health Professionals (AMSUS),Child Neurology Society, Southern Pediatric Neurology Society
Disclosure: Nothing to disclose.
Raj D Sheth, MD Chief, Division of Pediatric Neurology, Nemours Children's Clinic; Professor of Neurology, Mayo Clinic Alix School of Medicine; Professor of Pediatrics, University of Florida College of Medicine
Raj D Sheth, MD is a member of the following medical societies:American Academy of Neurology,American Academy of Pediatrics,American Epilepsy Society,American Neurological Association,Child Neurology Society
Disclosure: Nothing to disclose.
David A Chesler, MD, PhD Clinical Assistant Professor of Neurological Surgery and Pediatrics, Stony Brook University Hospital; Co-Director of Pediatric Neurosurgery, New York Spine and Brain Surgery, UFPC
David A Chesler, MD, PhD is a member of the following medical societies:American Association of Neurological Surgeons,American Medical Association,Congress of Neurological Surgeons,International Society of Pediatric Neurosurgery,Medical Society of the State of New York, Suffolk Pediatric Society
Disclosure: Nothing to disclose.
Faisal A Almayman, MBBS Post Doctorate Research Fellow, Department of Neurosurgery, Johns Hopkins University School of Medicine
Faisal A Almayman, MBBS is a member of the following medical societies:American Association of Neurological Surgeons, Saudi Stroke Association
Disclosure: Nothing to disclose.
Alvin Marcovici, MD Consulting Staff, Southcoast Neurosurgery
Alvin Marcovici, MD is a member of the following medical societies:American Association of Neurological Surgeons,Congress of Neurological Surgeons, andPhi Beta Kappa
Disclosure: Nothing to disclose.